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treatment line. Association between the annual treatment cost per patient and 
the attributes was studied using Pearson correlation coefficient (for quantitative 
variables), ANOVA (for qualitative variables), and generalized linear model using 
gamma distribution. Results: Annual treatment costs varied from 1,500€ to almost 
1,000,000€ . Bivariate analysis showed a significant association between the annual 
treatment cost and disease prevalence, age group, treatment line, alternative treat-
ments, therapeutic area, and ATC class (p< 0.05 for all). Significantly higher cost was 
observed in pediatric population, first treatment line, metabolic diseases, or in case 
of absence of alternative treatment. Multivariate analysis including these variables 
did not showed significant results. Given the complex correlation structure between 
the co-variates, the model including only the prevalence and alternative treatments 
was tested. Both co-variates were significant. ConClusions: Disease prevalence 
and unmet needs seems to be the main drivers of ODs prices while the level of 
clinical evidence and disease severity had no impact. However, this is difficult to 
justify statistically because of high variance and small number of observations. 
Interestingly, ASMR score presented by the HAS as main price driver was not shown 
having an impact on drug prices.
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objeCtives: New drugs launching into Germany undergo benefit assessment 
by G-BA, followed by a price negotiation with GKV-Spitzenverband (GKV-SV). In 
this paper we analyze the determinants of German rebate outcomes for oncol-
ogy drugs. Methods: We used the (Coveragedecisions} payer decision database 
as the basis of this analysis. This database consists of systematically abstracted 
data from publicly available payer decisions on pricing, reimbursement, HTA 
and formulary coverage decisions from 21 countries worldwide, covering all new 
molecular entities (NMEs) approved in EU or US since 2011. We extracted data from 
the (Coveragedecisions} payer decision database on G-BA benefit assessment and 
GKV-SV pricing outcomes of all oncology NMEs with a known GKV-SV pricing out-
come. The data extracted included G-BA benefit rating at subgroup level, relative 
sizes of subgroups, intervention and comparator costs by subgroups, time limi-
tations on benefit determination and magnitude of rebate. We then conducted a 
stepwise multiple linear regression with backward elimination, with magnitude 
of post-AMNOG rebate as the dependent variable, and benefit category, difference 
between intervention and comparator costs and presence of time limit on benefit 
recommendation as the independent variables. Results: Of the 27 benefit assess-
ments analyzed, rebates varied from 10%-54%. The final model (adjusted R square 
0.75; F statistic 9.35; p< 0.001) showed that the difference between intervention 
and comparator costs was a significant predictor of rebate (p= 0.004). Compared to 
‘indication of considerable benefit’, ‘no benefit’ (p= 0.001) and ‘hint of minor benefit’ 
(p< 0.001) were associated with significantly higher rebates. Though other benefit 
ratings did not achieve statistical significance, directionally, ‘proof of minor benefit’ 
and ‘indication of lower benefit’ were associated with higher rebates compared to 
‘indication of considerable benefit’. ConClusions: Based on our analysis, GKV 
rebate for oncology drugs can be expressed using a multiple regression equation, 
as a function of G-BA benefit rating category and incremental cost vs. comparator.
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objeCtives: The growing costs of medicines have forced many countries to imple-
ment measures to lower the prices of originators and generics after patent expira-
tion. Measures taken in Austria include Generic Price Linkage System, where there 
are strict upper limits for the prices of generics and also for originators after the 
entry of generics. Measures taken in Finland include Generic Substitution and 
Reference Pricing, where competition plays an important role. The aim of this 
study is to compare the effects of the measures taken in Austria and in Finland on 
the prices of originators and generics. Methods: We included in the analysis ten 
active ingredients whose sales were high in Finland, which were reimbursable in 
both countries, and whose patent protection expired during the years 2010–2012. 
The analysis was based on time series, which covered 6 months before and 12 
months after the entry of the first generic. The changes in price levels were meas-
ured in terms of wholesale prices proportioned to the number of Defined Daily 
Doses in the package (EUR/DDD). Results: One year after generic entry, prices 
for originators had fallen, on average, by 46% in Austria and by 21% in Finland. 
Prices for generics were 66% lower in Austria and 59% lower in Finland than the 
prices of originators before generic entry. The mean number of generics per active 
ingredient was 6.3 in Austria and 5.1 in Finland. ConClusions: The pricing sys-
tem applied in Austria appears to be more efficient in lowering prices than the 
system used in Finland, which contradicts claims that free competition lowers 
generic prices more efficiently than linking them to the price of the originator. 
This finding may be due to the way the Finnish Reference Price System has been 
constructed.
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objeCtives: Recent advances in treating Hepatitis C (HCV) have prompted sig-
nificant debate about affordability. The objective of this research was to investi-
gate Health Technology Assessment (HTA) agencies’ approach to assessment and 
the impact of evidence criteria on recommendations. Methods: HTA reports 
published on HCV since 2014 were reviewed. The four most frequently assessed 
drugs were further scrutinized in terms of clinical benefit, costs and recommen-
understand the total cost of ownership as this will become ever more important for 
future market access, reimbursement and financial discussions.
md3
the economic imPAct of the use of imPlAntAble cARdioveRteR 
defibRillAtoR in PRimARy PRevention
Madotto F1, Conti S1, Chiodini V1, Mantovani LG1, Achilli F2, Curnis A3, Landolina M4, 
Lunati M5, Marzegalli M6, Proclemer A7, Fornari C1, Cesana G1
1University of Milano-Bicocca, Monza, Italy, 2Cardiology AO San Gerardo de’ Tintori, Monza, 
Italy, 3Ospedali Civili, Brescia, Italy, 4Ospedale Maggiore, Crema, Italy, 5Ospedale Niguarda-Cà 
Granda, Milano, Italy, 6Fondazione “Maddalena Grassi”, Milano, Italy, 7Ospedale “S. Maria della 
Misericordia”, Udine, Italy
objeCtives: Given the high burden of cardiovascular diseases treated in primary 
prevention with the implantable cardioverter defibrillator (ICD), the monitor of 
healthcare expenditure related to such diseases is essential for health policy mak-
ers. This study assessed the variation in costs of patients with ICD over time, from 
3 years before the first implant up to 8 years after. Methods: Patients covered 
by Lombardy Healthcare System (HS) who underwent an ICD implantation in the 
period 2003-2010 were identified through regional healthcare administrative data-
bases (HAD). Data extracted from these HAD were linked with clinical information 
collected in the national ICD registry, and for each patient we selected the first 
implant performed in primary prevention. We identified drug prescriptions, hospi-
talizations and outpatient visits provided to patients for their cardiovascular disease 
during the 3 years before and the 8 years after the implant. For the same period, we 
estimated the trend in mean annual per capita cost through the Bang and Tsiatis 
method, that considers censoring in cost data. Results: Patients with a first ICD 
implanted in primary prevention were 6,936 (82% males, mean age 65 years) and 
we observed a yearly mortality rate of 6.9% (95% Confidence Interval (CI): 6.6-7.3) 
during follow-up. During the 3 years before the implant, the mean annual per capita 
cost was € 3,424 (95%CI: 3,331-3,537) and it increased to € 4,136 (95%CI: 4,004-4,262) 
after ICD implantation. However, before the ICD implantation we observed a grow-
ing trend in mean annual per capita costs, while after the intervention this trend 
was negative. ConClusions: Our study confirmed the high economic impact of 
cardiovascular diseases on the HS when treating subjects with left ventricular sys-
tolic dysfunctions or heart failure. Different trends in the healthcare expenditure 
were detected pre and post ICD implantation, but the significance of such difference 
should be further explored.
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objeCtives: 18F-FDG-PET/CT is accurate in detecting distant metastases (DM) 
in breast cancer patients scheduled for neoadjuvant chemotherapy. If DMs are 
screen-detected in an early phase, morbidity and mortality may be reduced. 
Because 18F-FDG-PET/CT comes at a significant cost, we compared its expected 
cost-effectiveness in stage II/III breast cancer patients of the UK, the US and the 
Netherlands (NL) vs. the gold-standard (X-thorax/liver sonography/bone scan (UK/
NL) and CT-thorax-abdomen/bone scan (US)). Methods: A time-dependent Markov 
model compared expected Life Year (LY) and cost/Quality-adjusted Life Year (QALY) 
gained in four breast cancer subtypes (ER-/HER2+;ER+/HER2+;ER-/HER2-;ER+/HER2-) 
over a 5-year time horizon from a hospital perspective. Sensitivity and specific-
ity of imaging and type of systemic and local treatments were derived from the 
Netherlands Cancer Institute. Epidemiological, survival and utility data were esti-
mated from literature or informed by expert assumptions. Costs (2013) were derived 
from national tariffs (UK and NL), and from the Centres for Medicaid and Medicare 
Services (US). Results: 18F-FDG-PET/CT is more sensitive (53% vs. 15%) and specific 
(97% vs. 94%) than the gold-standard. LYs and QALYs gained were similar across 
subtypes, ranging from 0.025 to 0.027 and 0.0037 to 0.0044 respectively. In all coun-
tries, ER+HER2+ was the least and ER+HER2- the most costly group. 18F-FDG-PET/
CT is expected to be cost-effective in the NL and the US (with highest ICERs of € 165/
QALY in ER+/HER2+ and $750 in ER-HER2+), with probabilities of cost-effectiveness 
ranging from 46-52% and 62-72% respectively, but not in the UK, with a 66-75% prob-
ability, depending on tumor subtype. ConClusions: Using 18F-FDG-PET/CT for DM 
screening in stage II/III breast cancer is expected to result in incremental QALY gains 
in all subtypes and countries. Due to costs differences between countries, 18F-FDG-
PET/CT is expected to be cost-effective in the US and the NL, but not in the UK.
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objeCtives: No specific market access process has been developed for orphan 
drugs (ODs) in France, but there is an unspoken will to support these medicines. 
Pricing process of ODs is unclear, and many of them became blockbusters despite 
the small size of the targeted population. The aim of the study is to identify the 
main drivers of ODs prices in France. Methods: ODs prices were extracted from 
Ameli database. Drugs and diseases attributes were defined based on the reports 
of the European Medicines Agency and Haut Authorité de Santé (HAS). Attributes 
included the prevalence, ATC class, therapeutic area, disease severity, alternative 
treatments, level of clinical evidence, SMR and ASMR scores, year assessment, and 
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objeCtives: This analysis aimed to investigate potential differences in estimated 
survival outcomes between partitioned survival models and state transition 
(Markov) models in the common three-state model of pre-progression, post-progres-
sion, and death by using nivolumab trial data in advanced melanoma. Methods: 
Each approach was applied separately to patient-level data from a phase 1b trial of 
nivolumab in 304 patients with previously treated advanced solid tumors (107 mela-
noma patients). All patients were included in parametric survival analyses (with a 
parameter identifying melanoma patients) to model overall survival (OS), progres-
sion free survival (PFS), and post-progression survival (PPS) to extrapolate (10 years) 
beyond maximum trial follow-up for melanoma patients specifically. Alternative 
fits to the data were compared on the basis of Akaike Information Criterion (AIC) 
and the plausibility of the long-term extrapolation. Results: The Weibull para-
metric model was judged to be the most conservative in terms of extrapolation 
and forms the basis of these results. Log-normal and log-logistic generally had 
better fit in terms of AIC, but fatter tails were less suitable for extrapolation. The 
area under the curve (AUC) for extrapolated PFS and OS was 23.5 and 41.5 months, 
respectively, suggesting 18 months of PPS using the partitioned survival approach. 
The AUC for PPS was 12.5 months, which gives an estimated OS of 36 months under 
the Markovian assumption. Relaxing this assumption to allow time dependency 
for transitioning between states with a Weibull model for PPS gives an estimated 
PPS of 17.1 months and an OS of 40.6 months. ConClusions: Partitioned sur-
vival modeling and Markov modeling make intrinsically different assumptions; 
nevertheless, by relaxing the Markovian assumption and allowing time dependency, 
the two modeling forms are shown to be functionally equivalent. The selection of 
approach should be driven by what best represents the disease, treatment effect, 
and available clinical data.
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objeCtives: To compare the economic results of a non-randomized study using 
propensity score (PS) methodology to adjust for confounding versus a restriction 
approach based on clinical opinion. Methods: We used data from a published 
non-randomized study, which enrolled 195 patients (58.2%) to receive open surgi-
cal repair (OSR) and 140 patients (41.8%) to receive endovascular aneurysm repair 
(EVAR) for the treatment of abdominal aortic aneurysm. OSR patients were classi-
fied as being at low risk (LR) or high risk (HR) for post-surgical complications based 
on clinical opinion and scoring algorithms while all EVAR patients were classified 
as HR. The database included baseline characteristics, patient level 1-year cost 
and survival data. One-to-one PS matching was used within the full population 
to select a more balanced patient sub-population. Incremental cost-effectiveness 
ratios (ICERs) were assessed within the HR sub-population and the PS-matched 
sub-population. Results: The HR sub-population was composed of all 140 EVAR 
patients (100.0%) and 50 OSR patients (25.6%). EVAR was identified as the dominant 
treatment option within the HR sub-population. The PS-matched sub-population 
was composed of 77 HR EVAR patients (55.0%) and 77 OSR patients (39.5%), of which 
48 (62.3%) were OSR-LR patients and 29 (37.7%) were OSR-HR patients. Unlike results 
obtained within the HR sub-population, the ICER of EVAR was estimated at $93,608 
per life-year gained within the PS-matched sub-population. Differences in the 
results may be explained by confounding; although balance was improved within 
the PS-matched sub-population, unbalance remained on several patient charac-
teristics. ConClusions: Results of this study highlight the fact that PS matching 
may not always fully adjust for confounding. Clinical opinion may be influenced by 
unmeasured confounders which may not be adjusted for by PS matching. Balance 
within patient subsets following PS matching must be evaluated when conducting 
economic evaluation based on non-randomized studies, especially in studies with 
small sample sizes.
vAccine studies
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objeCtives: Final phase III trial results of the first malaria vaccine candidate RTS,S 
have been published. Based on these results, our study aims at estimating the public 
health impact and cost-effectiveness of RTS,S implementation in infants in 42 sub-
Saharan countries. Methods: We developed a stochastic individual-based Markov 
model, calibrated against data from the control and vaccine arms of the RTS,S 
vaccine trial, published age distribution data and case-fatality rate. The simulated 
2017 birth cohort was vaccinated at 6, 10, 14 weeks without and with a 4th dose at 
21 months of age and followed-up over 15 years. Impact of sequelae and mortality 
was accounted over lifetime. Country-specific inputs were demographics, parasite 
prevalence, access to care, and diphtheria-tetanus-pertussis third dose vaccina-
tion coverage (DTP-coverage), with RTS,S 4th dose coverage assumed at 80% DTP-
coverage. Costs for malaria outpatient visits and hospitalizations were taken from 
a study in 3 sub-Saharan countries. RTS,S price and cost of administration per dose 
dation. Results: Forty-two assessments were published. Of these, sofosbuvir 
was the focus of 29% of assessments, followed by simeprevir (26%), daclatasvir 
(12%) and ledipasvir + sofosbuvir (12%). These 33 HTAs met the criteria for fur-
ther analysis. Eleven recommendations were positive without restriction (33%); 
20 were positive with restrictions (60%) and two were negative (6%). Ledipasvir + 
sofosbuvir received the lowest proportion of positive recommendations without 
restriction (20%). Simeprevir and daclatasvir had the highest proportions, with 
41% and 41%, respectively. Sofosbuvir, the first marketed and highest priced, was 
the only drug to receive negative recommendations. Clinical benefit was recog-
nised as being an important criteria in 19 (58%) of the 33 reports. The main nega-
tive critique (reported in 11/33 cases) was lack of direct comparative evidence 
and the resulting uncertainty around cost-effectiveness. In three cases, positive 
recommendations were based on price negotiations with the manufacturer. The 
20 positive recommendations were restricted to subpopulations where the cost-
effectiveness was highest (progressed patients, with fibrosis and facing transplan-
tation). ConClusions: Recently, 4 effective, but costly HCV drugs were launched. 
No clear trend was observed regarding order of market entry and HTA recommen-
dation. However, in most cases, agencies restricted access to subpopulations. Cost 
seemed to be a key decision driver: simeprevir and daclatasvir most often received 
a positive recommendation.
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objeCtives: Participants in oncology randomised controlled trials (RCT) are often 
permitted to switch from their randomised treatments onto alternative treat-
ments. Intention-to-treat (ITT) assessments are prone to bias in the presence of 
switching and consequently the overall survival (OS) benefit and cost-effectiveness 
of the novel treatment may be underestimated. Regardless, decision-makers fre-
quently reject statistical analyses which adjust for treatment switching in health 
technology assessment, often due to poor justification of methodological assump-
tions. This study applies adjustment methods to an RCT comparing dabrafenib 
to dacarbazine in patients with BRAF V600E/K mutation-positive metastatic mel-
anoma, and investigates which adjustment method best fits this specific case 
study. Methods: The adjustment methods applied included the Rank Preserving 
Structural Failure Time Model (RPSFTM), Inverse Probability of Censoring Weights 
(IPCW), and two-stage adjustment. The suitability of each method was assessed 
by investigating their assumptions and trial characteristics. Results: 37/63 
(58.7%) dacarbazine patients switched to dabrafenib (direct switching). Also, 16 
(25.4%) dacarbazine patients and 27 (14.4%) of 187 dabrafenib patients received 
other small molecule targeted treatments post-study (indirect switching). The 
ITT hazard ratio (HR) for OS was 0.81 (95% confidence intervals (CI) 0.56 - 1.16,) 
favouring dabrafenib. An RPSFTM analysis to adjust for direct switching, com-
bined with a two-stage analysis to adjust for indirect switching, appeared most 
appropriate, producing an adjusted HR of 0.68 (95% CI 0.33 - 1.63). It was not pos-
sible to robustly adjust for direct and indirect switching simultaneously using 
standalone IPCW or two-stage methods due to small patient and event numbers. 
Whilst it is not possible to perfectly test the common treatment effect assumption 
required by the RPSFTM, our investigations did not find strong evidence against 
this. ConClusions: Adjusting for switching showed an increased OS effect for 
dabrafenib. Methodological assumptions must be rigorously investigated to dem-
onstrate whether and which adjustment methods are justified.
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objeCtives: The standard approach to derive transition probabilities for use in 
state-transition cost-effectiveness models based on available risk functions with dif-
ferent time horizon than the model cycle length is to use an exponential distribution 
(constant event rate assumption) to derive model cycle risk. However this does not 
remove any age effect on risk, resulting in potential overestimation of cycle-specific 
risks in the case age is included as a risk factor. We present an approach for annuali-
zation of event risk predictions that ensures the correct risk is predicted. Methods: 
The proposed approach ensures that the starting age-specific event rate multiplied 
by the cumulative effect of increasing age during the time horizon of the risk func-
tion equals the original risk prediction. To illustrate and compare the standard and 
the proposed approach, 10-year risk is modelled and compared to the initial 10-year 
predicted risk using the latest Framingham risk function for primary cardiovascular 
(CVD) event risk (D’Agostino et al. 2008). Scenarios are investigated using different 
starting age and different initial predicted risk level. Results: The standard risk 
annualization approach consistently overestimates the modelled risk over a 10-year 
horizon compared with the initial risk prediction for the same period. To illustrate, 
for a 50-year old male with initial 10-year CVD risk of 20%, 30% or 40% the corre-
sponding modelled risk is 25%, 37% and 49%, respectively. The proposed method for 
risk annualization provides the exact 10-year initial risk. ConClusions: Careful 
application of approach for time period adjustment of existing risk functions for use 
in state-transition models is needed when age is included as a risk factor and the 
model cycle length differs from the time horizon of the risk function. The standard 
risk annualization approach will lead to an overestimation of modelled risk and a 
more favorable estimate of cost-effectiveness.
